Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations & Communications Josh Cohen - Co-CEO & Co-Founder Justin Klee - Co-CEO & Co-Founder Margaret Olinger - Chief Commercial Officer James Frates - Chief Financial Officer Conference Call Participants Corinne Jenkins - Goldman Sachs Geoff Meacham - Bank of America Umer Raffat - Evercore ISI Marc Goodman - Leerink Partners Graig Suvannavejh - Mizuh ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | |----------------------------------------------------------------------------------------------------| | | | For the transition period from ___________________ to | | Commission F ...

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Lindsey Allen - Head of Investor Relations & Communications Justin Klee - Co-Chief Executive Officer Margaret Olinger - Chief Commercial Officer Jim Frates - Chief Financial Officer Josh Cohen - Co-Chief Executive Officer Conference Call Participants Corinne Jenkins - Goldman Sachs Geoff Meacham - Bank of America Michael DiFiore - Evercore Marc Goodman - Leerink Partners Graig Suvannav ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | |-----------------------------------------------------------------------------------------------------| | | | For the transition period from ___________________ to ___________________ ...

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer and Co-Founder Margaret Olinger - Global Head of Commercial and CCO James Frates - Chief Financial Officer Josh Cohen - Co-Chief Executive Officer and Co-Founder Conference Call Participants Corinne Jenkins - Goldman Sachs Marc Goodman - SVB Securities Ananda Ghosh - H.C. Wainwright Neen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |----------------------------------------------------------------------------------------------------|------------------------------------------| | | | | For the transition peri ...

Investor Presentation April 2023 photo in memory of Mick, a husband and father, who was a gifted tattoo artist and musician Disclaimer Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statement ...

Investor Presentation March 2023 photo in memory of Mick, a husband and father, who was a gifted tattoo artist and musician Disclaimer Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statement ...

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer and Co-Founder Margaret Olinger - Global Head of Commercial and CCO James Frates - Chief Financial Officer Josh Cohen - Co-Chief Executive Officer and Co-Founder Conference Call Participants Geoff Meacham - Bank of America Umer Raffat - Evercore ISI Neena Bitritto-Garg - Citi Corinne J ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41199 Amylyx Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) Delaware 46-4600503 (State or other jurisdi ...